CAC 40
7 957,57 +42,92 (+0,54 %) Euro Stoxx 50
4 921,48 +30,87 (+0,63 %) Dow Jones
38 675,68 +450,02 (+1,18 %) EUR/USD
1,0765 +0,0038 (+0,36 %) Gold future
2 310,10 +0,50 (+0,02 %) Bitcoin EUR
59 205,50 +734,62 (+1,26 %)
Corcept Therapeutics Incorporated (CORT)
Échanges après Bourse :
Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270
https://www.corcept.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 352
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, CEO & Director | 2,43M | S.O. | 1957 |
| Mr. Atabak Mokari | CFO & Treasurer | 863,03k | S.O. | 1977 |
| Mr. Sean Maduck | President of Endocrinology | 1,05M | 2,7M | 1977 |
| Dr. William Guyer Pharm.D. | Chief Development Officer | 1,03M | 135k | 1968 |
| Mr. Gary Charles Robb | Chief Business Officer & Secretary | 1,08M | 3,01M | 1963 |
| Mr. Joseph Douglas Lyon | Chief Accounting & Technology Officer | S.O. | S.O. | 1978 |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer | 895,16k | 1,75M | 1960 |
| Ms. Amy Flood | Chief Human Resources & Communications Officer | S.O. | S.O. | S.O. |
| Ms. Monica Tellado | President of Emerging Markets | S.O. | S.O. | 1973 |
| Mr. Roberto W. Vieira | President of Oncology | S.O. | S.O. | S.O. |
Description
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Corcept Therapeutics Incorporated en date du 1 mai 2024 est 5. Les scores principaux sont Audit : 4; Société : 4; Droits des actionnaires : 6; Compensation : 7.
